skip to Main Content

Clinical Trial Shows Experimental Drug’s Ability to Knock Down Pancreatic Cancer’s Defense

Newsfeed image, light gray text on dark gray background
By adding an experimental drug to a standard chemotherapy regimen, a subset of patients with metastatic pancreatic cancer had a significantly longer period before the cancer progressed as compared with those who received the standard treatment, according to a Phase 2 clinical trial led by an investigator at Fred Hutchinson Cancer Research Center.

The randomized, controlled trial found that when the experimental therapy was given to participants whose tumors had a lot of the drug’s target molecule, they had four months more of progression-free survival than participants in the control group who only had the chemo. Read more . . .

Back To Top